Sarepta Therapeutics, Inc. (SRPT)
Automate Your Wheel Strategy on SRPT
With Tiblio's Option Bot, you can configure your own wheel strategy including SRPT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SRPT
- Rev/Share 22.9388
- Book/Share 11.7368
- PB 3.2896
- Debt/Equity 1.1759
- CurrentRatio 4.0168
- ROIC -0.062
- MktCap 3794474970.0
- FreeCF/Share -7.0618
- PFCF -5.5188
- PE -15.1342
- Debt/Assets 0.3878
- DivYield 0
- ROE -0.2
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | SRPT | Evercore ISI | Outperform | In-line | -- | $50 | May 8, 2025 |
| Initiation | SRPT | Wells Fargo | -- | Overweight | -- | $115 | April 11, 2025 |
| Upgrade | SRPT | H.C. Wainwright | Sell | Neutral | -- | $75 | April 2, 2025 |
| Downgrade | SRPT | RBC Capital Mkts | Outperform | Sector Perform | $161 | $87 | March 31, 2025 |
| Initiation | SRPT | Deutsche Bank | -- | Hold | -- | $136 | Feb. 11, 2025 |
| Initiation | SRPT | Jefferies | -- | Buy | -- | $165 | Oct. 21, 2024 |
| Resumed | SRPT | Raymond James | -- | Outperform | -- | $150 | Oct. 10, 2024 |
News
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Published: March 31, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Sarepta Therapeutics, Inc. (SRPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Published: March 28, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: March 27, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: March 26, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Stockholders to Inquire about Securities Investigation
Published: March 26, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: March 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , March 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ:SRPT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect
Published: March 24, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Read More
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sarepta Therapeutics, Inc. (SRPT) and Encourages Stockholders to Learn More About the Investigation
Published: March 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
Sarepta: Should Investors Run For The Exit?
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Positive
Shares of Sarepta Therapeutics dropped 20% after a patient died from acute liver injury post-ELEVIDYS treatment, an event not previously reported. Despite the tragic news, we believe this is an isolated incident, influenced by the patient's recent CMV infection, and not indicative of systemic issues. With over 800 patients treated and no similar cases, we expect the stock to recover, presenting a buying opportunity for risk-tolerant investors.
Read More
Bronstein, Gewirtz & Grossman, LLC Encourages Sarepta Therapeutics, Inc. (SRPT) Investors to Inquire about Securities Investigation
Published: March 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:SRPT). Investors who purchased Sarepta securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SRPT.
Read More
Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Read More
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD).
Read More
S&P 500 Down 1%; Sarepta Therapeutics Shares Plunge
Published: March 18, 2025 by: Benzinga
Sentiment: Negative
U.S. stocks traded lower midway through trading, with the S&P 500 falling around 1% on Tuesday.
Read More
Sarepta Therapeutics faces new safety concerns for gene therapy ELEVIDYS following patient death
Published: March 18, 2025 by: Proactive Investors
Sentiment: Negative
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares plunged more than 21% after it revealed a patient with Duchenne muscular dystrophy (DMD) has died following treatment with its gene therapy ELEVIDYS. Although acute liver injury is a known potential side effect of ELEVIDYS and similar therapies, this level of severity had not been previously reported, the company said in a statement.
Read More
Sarepta Therapeutics' stock falls after patient dies of liver failure
Published: March 18, 2025 by: Market Watch
Sentiment: Negative
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Read More
Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
Published: February 28, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the official opening of Route 79, The Duchenne Scholarship Program for the 2025-2026 academic year. Academic scholarships of up to $5,000 will be awarded to as many as 20 individuals living with Duchenne muscular dystrophy and 5 siblings of individuals living with Duchenne. “In the past decade, there have been significant advancements in the tr.
Read More
Sarepta Therapeutics, Inc. (SRPT) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations and Corporate Communications Doug Ingram - President and CEO Ian Estepan - Executive Vice President and CFO Dallan Murray - Executive Vice President and CCO Dr. Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer and Head, Research & Development Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Gena Wang - Barclays Andrew Tsai - Jefferies Kostas Biliouris - BMO Capital Markets Mike Ulz - Morgan Stanley Joe Schwartz …
Read More
Sarepta Therapeutics (SRPT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Published: February 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Sarepta Therapeutics Announces Inaugural $600 Million Senior Secured Revolving Credit Facility
Published: February 14, 2025 by: Business Wire
Sentiment: Neutral
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility with a bank syndicate. "Sarepta's financial strength and the positive outlook for our business provide us with the flexibility to use non-dilutive financing by establishing a revolving credit facility. It supplements our strong balance sheet and allows for contingent.
Read More
About Sarepta Therapeutics, Inc. (SRPT)
- IPO Date 1997-06-04
- Website https://www.sarepta.com
- Industry Biotechnology
- CEO Mr. Douglas S. Ingram Esq.
- Employees 1372